What is the purpose of this trial?
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
Start Date: 05/23/2017
End Date: 10/01/2019
Last Updated: 12/04/2018
Study HIC#: 2000020229